menu
    • menu

    Company profile for Xiromed

    NEW Drugs in Dev: 4
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Xiromed is the newest division in the Insud Pharma family of companies focused on bringing high quality generic pharmaceuticals to the US market. Xiromed joins brand company Exeltis in the US market and is supported by Chemo industrial in Spain. At Xiromed, we work from the absolute commitment to develop products created from the highest quality pharmaceutical ingredients & using the most advanced technology in the sector. Th...
    Xiromed is the newest division in the Insud Pharma family of companies focused on bringing high quality generic pharmaceuticals to the US market. Xiromed joins brand company Exeltis in the US market and is supported by Chemo industrial in Spain. At Xiromed, we work from the absolute commitment to develop products created from the highest quality pharmaceutical ingredients & using the most advanced technology in the sector. This, together with the Insud Pharma’s resources, professional talent and years of experience allow us to offer solutions & products in different formats & presentations: Oral solids, inhalation, hormonal, injectable etc

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    XiromedUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    180 Park Ave ,Suite 101 Florham Park, NJ 07932
    Telephone
    Telephone
    (844-947-6633)
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://xiromed.com/usa/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Xiromed’s Generics Clobetasol Propionate Receives Approval in US
    Xiromed’s Generics Clobetasol Propionate Receives Approval in US

    20 Nov 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210638

    FDA
    20 Nov 2025
    Share Share
    Xiromed’s Receives First Generic Approval for Progesterone in US
    Xiromed’s Receives First Generic Approval for Progesterone in US

    19 Sep 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=218391

    FDA
    19 Sep 2025
    Share Share
    Xiromed`s Generics Selenious Receives Tentative Approval in US
    Xiromed`s Generics Selenious Receives Tentative Approval in US

    12 Jun 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219476

    FDA
    12 Jun 2025
    Share Share
    Xiromed`s Generic Guanfacine Hydrochloride Receives Approval in the U.S.
    Xiromed`s Generic Guanfacine Hydrochloride Receives Approval in the U.S.

    23 Feb 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218326

    FDA
    23 Feb 2024
    Share Share
    Xiromed's Generic Levonorgestrel and Ethinyl Estradiol Receives Approval in the U.S.
    Xiromed's Generic Levonorgestrel and Ethinyl Estradiol Receives Approval in the U.S.

    16 Aug 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214640

    FDA
    16 Aug 2023
    Share Share
    Xiromed's Generic Ramelteon Receives Approval in the U.S.
    Xiromed's Generic Ramelteon Receives Approval in the U.S.

    25 Nov 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216209

    FDA
    25 Nov 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search